Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
Infertility
Interventions
DRUG

Progestin primed ovarian stimulation

HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.

DRUG

GnRH antagonist

HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.

Trial Locations (1)

Unknown

Bedaya Hospital, Giza

All Listed Sponsors
lead

Bedaya Hospital

OTHER